The First Report of NRG Oncology/RTOG 0622: A Phase 2 Trial of Samarium 153 Followed by Salvage Irradiation in High-Risk Nonmetastatic Prostate Cancer After Prostatectomy

      The main objective of NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0622 was to assess the prostate-specific antigen (PSA) response of Samarium 153 administration for an isolated PSA rise after prostatectomy. Secondary endpoints were hematological and other adverse events.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.